Results 101 to 110 of about 765,112 (149)

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 22, Page 6574-6606, November 2026.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown   +2 more
wiley   +1 more source

Structural basis for chromosome X-linked agammaglobulinemia: a tyrosine kinase disease.

open access: yes, 1994
X-linked agammaglobulinemia (XLA) is a hereditary defect of B-cell differentiation in man caused by deficiency of Bruton tyrosine kinase (BTK). A three-dimensional model for the BTK kinase domain, based on the core structure of cAMP-dependent protein ...
Zhu, Qili   +9 more
core   +3 more sources

Exploring the association of disease-modifying therapies for multiple sclerosis and BTK inhibitors with epilepsy

open access: yesTherapeutic Advances in Neurological Disorders
Background: Multiple lines of evidence suggest a role of inflammation in epilepsy. Seizure incidence in patients with multiple sclerosis (MS) is twofold to threefold higher than the age-matched general population.
Afsaneh Shirani   +6 more
doaj   +1 more source

Is Bruton tyrosine kinase a potential target to treat mast cell neoplasms? Systemic mastocytosis associated with chronic lymphoid leukemia successfully treated with acalabrutinib monotherapy: a case report and review of the literature

open access: yesHaematologica
Not available.
Manlio Fazio   +8 more
doaj   +1 more source

Thermodynamic characterisation of covalent ligand binding

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 22, Page 6704-6717, November 2026.
Background and Purpose Differential scanning fluorimetry (DSF) is a common and straightforward method to evaluate the thermal stability of proteins and has been heavily used for ligand binding characterisation as well as for screening. One class of compounds that is less typically evaluated by DSF are covalent binders.
Rebecca Hertzman   +4 more
wiley   +1 more source

Bruton tyrosine kinase inhibitors in combination with chemoimmunotherapy is an effective treatment for patients with Richter’s syndrome

open access: yesLeukemia Research Reports
Richter’s syndrome (RS) is characterized by transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) into an aggressive lymphoma.
Tristan Meier   +4 more
doaj   +1 more source

Application of Mechanistic Modeling to Support Dose‐Relevant Decision Making for CAR‐T Cell Therapy in Oncology: A Systematic Scoping Review

open access: yesClinical and Translational Science, Volume 19, Issue 11, November 2026.
ABSTRACT CAR‐T therapy has improved outcomes in selected relapsed or refractory hematologic malignancies. However, rational dose‐relevant decision application remains challenging because the administered (nominal) cell dose does not reliably predict in vivo exposure, toxicity, or clinical response.
Dolapo Odujinrin, Graham McClelland
wiley   +1 more source

Early Integration of CAR T‐Cell Therapy in Mantle Cell Lymphoma: Expert Opinion in the Era of BTK Inhibitors

open access: yes
Hematological Oncology, Volume 44, Issue 6, November 2026.
Carlo Visco   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy